“Today’s announcement was a worst-case scenario for Cardinal Health’s Optum renewal,” EvercoreISI analyst Elizabeth Anderson wrote in a note.
Ipsen is looking to deepen its expertise in movement disorders in a research collaboration with Skyhawk Therapeutics to develop small molecule drugs for RNA targets in neurological diseases.
Could stem cell therapies make the Parkinsonian brain generate dopamine again? Some companies, including BlueRock Therapeutics and International Stem Cell Corporation, are banking on it.
Drugmakers, including the genetic testing company 23andMe, are using novel approaches to stimulate NK cells’ intrinsic ability to recognize and kill tumor cells.
CVS Health has lost a bid to escape a proposed class action lawsuit accusing the company of discriminating against people with HIV by requiring them to receive their medications by mail.
Though a Sanofi spokesperson declined to provide details about the operations overhaul, including its timeline, scope and the number of employees that will be terminated, they said that the changes are part of Sanofi’s push to implement “a streamlined strategic sales structure.”
